NASDAQ:KERX - Keryx Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.90 -0.08 (-1.61 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$4.90
Today's Range$4.86 - $5.0457
52-Week Range$3.92 - $8.38
Volume1.64 million shs
Average Volume977,832 shs
Market Capitalization$600.22 million
P/E Ratio-5.57
Dividend YieldN/A
Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Receive KERX News and Ratings via Email

Sign-up to receive the latest news and ratings for KERX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio-3.96
Current Ratio2.66
Quick Ratio1.87


Trailing P/E Ratio-5.57
Forward P/E Ratio-8.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$60.64 million
Price / Sales9.74
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-40.83


EPS (Most Recent Fiscal Year)($0.88)
Net Income$-163,440,000.00
Net Margins-230.00%
Return on Equity-10,954.62%
Return on Assets-60.47%


Outstanding Shares120,530,000

The Truth About Cryptocurrencies

Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals (NASDAQ:KERX) released its quarterly earnings results on Friday, May, 11th. The biopharmaceutical company reported ($0.18) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.18). The biopharmaceutical company had revenue of $21.75 million for the quarter, compared to analysts' expectations of $21.80 million. Keryx Biopharmaceuticals had a negative net margin of 230.00% and a negative return on equity of 10,954.62%. View Keryx Biopharmaceuticals' Earnings History.

When is Keryx Biopharmaceuticals' next earnings date?

Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Keryx Biopharmaceuticals.

What price target have analysts set for KERX?

4 Wall Street analysts have issued 12 month price objectives for Keryx Biopharmaceuticals' shares. Their predictions range from $5.00 to $9.00. On average, they anticipate Keryx Biopharmaceuticals' share price to reach $6.6667 in the next year. View Analyst Ratings for Keryx Biopharmaceuticals.

What are Wall Street analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Auryxia posted a good performance in 2017.  The FDA approval for the label expansion of Auryxia to treat adults with iron deficiency anemia (IDA) and chronic kidney disease, not on dialysis, might boost sales of the company, given that the IDA market holds great potential. However, with Auryxia being the only approved product in Keryx’s portfolio, the company is completely dependent on it for growth. Meanwhile, Auryxia faces stiff competition in the United States from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Also, Keryx may face strong pricing pressure for Auryxia. The company did not provide any guidance for 2018 as the company waits to see how Auryxia is adopted by the patients in the IDA setting. Consequently, shares of the company underperformed the industry." (4/11/2018)
  • 2. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)

Who are some of Keryx Biopharmaceuticals' key competitors?

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:
  • Mr. Gregory P. Madison, CEO, Pres & Director (Age 50)
  • Mr. Scott A. Holmes, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 44)
  • Mr. Brian R. Adams, Sr. VP, Gen. Counsel & Sec. (Age 44)
  • Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
  • Ms. Christine A. Carberry, Sr. VP & COO (Age 57)

Has Keryx Biopharmaceuticals been receiving favorable news coverage?

Media stories about KERX stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a news sentiment score of 0.19 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.83 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Keryx Biopharmaceuticals' major shareholders?

Keryx Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.10%), Northern Trust Corp (0.92%), Millennium Management LLC (0.78%), Schwab Charles Investment Management Inc. (0.45%), Summit Trail Advisors LLC (0.28%) and Boston Partners (0.22%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Christine A Carberry, Greg Madison, John F Neylan, Kevin J Cameron, Scott A Holmes and Steven C Gilman. View Institutional Ownership Trends for Keryx Biopharmaceuticals.

Which major investors are selling Keryx Biopharmaceuticals stock?

KERX stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Chicago Equity Partners LLC, BlackRock Inc. and Northern Trust Corp. Company insiders that have sold Keryx Biopharmaceuticals company stock in the last year include Brian Adams, Christine A Carberry, Greg Madison, John F Neylan, Kevin J Cameron, Scott A Holmes and Steven C Gilman. View Insider Buying and Selling for Keryx Biopharmaceuticals.

Which major investors are buying Keryx Biopharmaceuticals stock?

KERX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Summit Trail Advisors LLC, UBS Group AG, Mackay Shields LLC, Meridian Wealth Management LLC, Russell Investments Group Ltd., Swiss National Bank and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Keryx Biopharmaceuticals.

How do I buy shares of Keryx Biopharmaceuticals?

Shares of KERX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Keryx Biopharmaceuticals' stock price today?

One share of KERX stock can currently be purchased for approximately $4.90.

How big of a company is Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals has a market capitalization of $600.22 million and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Keryx Biopharmaceuticals employs 210 workers across the globe.

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DRIVE, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]

MarketBeat Community Rating for Keryx Biopharmaceuticals (KERX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  422 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  690
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.